brukinsa (Zanubrutinib)

Zanubrutinib For The Treatment Of Patients With Waldenström Macroglobulinemia: 3 Years Of Follow-Up

Zanubrutinib For The Treatment Of Patients With Waldenström Macroglobulinemia: 3 Years Of Follow-Up

Abstract

In the October 29, 2020 issue of the journal Blood, investigators reported on the utility of zanubrutinib in both newly diagnosed as well as relapsed refractory Waldenstrom’s macroglobulinemia.  Patients were treated with 160 mg of oral zanubrutinib twice daily or 320 mg once daily.  There were 50 and 23 patients in each of those dosing arms, respectively.  Efficacy endpoints included overall response rate and very good partial response/complete response rates per the International workshop on Waldenstrom’s macroglobulinemia–6 criteria.  

77 patients, 24 with newly diagnosed disease and 53 with relapsed / refractory disease started treatment.  At a median follow-up of 36 months, patients who had relapsed refractory disease, 72.7% of patients remained on treatment. Reasons for treatment discontinuation were either from adverse events, disease progression or other reasons.  The overall response rate was 95.9% and a very good partial response/complete response was seen in 45.2%.  There was a substantial improvement in the response rates over time-20.5% in 6 months, 32.9% at 12 months and 43.8% in 24 months.  The estimated 3-year progression free survival rate was 8.5% and the overall survival rate was 84.8%.  Adverse events included contusion seen in 32.5% as well as neutropenia seen at 18.2%.  A small risk of major hemorrhage was documented, 3.9% with atrial fibrillation / atrial flutter seen in 5.2% of patients. Grade 3 diarrhea was seen in 2.6% of patients.  

The authors concluded “long-term treatment with single agents and ibrutinib resulted in deep and durable responses and some patients of alterations macroglobulinemia.  The safety profile of long-term zanubrutinib therapy in these patients was acceptable.”

https://ashpublications.org/Blood/article/136/18/2027/461544/Zanubrutinib-for-the-treatment-of-patients-with

en_USEnglish